Should you buy Neil Woodford’s top 3 holdings Imperial Brands plc, AstraZeneca plc & GlaxoSmithKline plc?

Edward Sheldon looks at the top three holdings of one of the UK’s best known fund managers, Neil Woodford: Imperial Brands plc (LON: IMB), AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford is among the most well-known fund managers in the UK. Given his star status, many private investors monitor Woodford’s key holdings in an attempt to clone his investment strategy.

So let’s look at the top three holdings in the Woodford Equity Income Fund and examine if they’re worth buying.

Financial market volatility

But first, let’s remember that there could be a great deal of near-term volatility in the financial markets after Friday’s EU referendum Brexit vote. The unexpected result has caused unprecedented amounts of uncertainty and if there’s one thing financial markets don’t like, it’s uncertainty.

Having said that, Woodford has made his stance clear on the result and has said he believes Britain’s long-term economic future will be largely unaffected by the decision to leave the EU. He’s also stated that his portfolio strategy will not change.

So with that in mind, here are Neil Woodford’s largest holdings.

Tobacco King

Woodford’s largest holding (7.6% of the fund) is tobacco giant Imperial Brands (LSE: IMB).

Tobacco stocks don’t suit everyone’s investing tastes, but Woodford has made it clear that he remains a strong fan of both Imperial Brands and rival British American Tobacco.

There’s no doubt Imperial Brands has performed well for his portfolio. The stock has delivered total annualised returns of almost 18% per annum over the last five years. But is this a reason to buy Woodford’s largest holding?

For me, the key question with Imperial Brands comes down to the long-term sustainability of tobacco revenues. I generally look for long-term revenue drivers when searching for investment opportunities, and personally I’m not 100% convinced about the sustainability of the tobacco industry over time.

Having said that, I can see plenty of reasons why investors could be interested in buying Imperial Brands right now though. The stock trades on a respectable P/E ratio of 15.5 times next year’s earnings, yields an excellent dividend of just under 4%, has high levels of free cash flow and could be seen as a ‘defensive’ stock in times of uncertainty.

Another key benefit of Imperial Brands is that it generates revenues from all over the world, so a weaker pound would be good for earnings. If you’re interested in a safety stock for the current volatile environment, Imperial Brands could be worth a look.

Healthcare theme

Woodford’s next two largest holdings are healthcare giants AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) at 7.2% and 6.4% of the portfolio, respectively.

Healthcare is a theme that I like and with the global population ageing, I believe it’s a theme that could drive long-term revenues going forward. It’s also one that could provide some insulation from Brexit-related market volatility as healthcare is also considered to be a defensive sector.

While both companies have struggled for revenue growth over the last few years, a key attraction of these stocks is their sizeable dividend payouts. AstraZeneca yields around 5.1% while GlaxoSmithKline pays out an even bigger 5.4%.

One concern is that last year both companies’ dividends exceeded their earnings from continuing operations, which isn’t ideal. It’s an issue to keep an eye on going forward in the current volatile market. However, I can see the attraction of buckling down with these two healthcare powerhouses.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Landlady greets regular at real ale pub
Investing Articles

How much is needed in an ISA to target a £2,741 monthly passive income?

James Beard explains how an ISA and a successful long-term stock-picking strategy could generate passive income matching the UK’s average…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Dividend Shares

How £2k invested in this passive income gem could make £1,092 annually

Jon Smith points out a dividend stock with a yield above 10% he thinks is both sustainable and also has…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

What’s wrong with Aviva and its share price?

The Aviva share price is up by double-digits over the last 12 months, but could this momentum be about to…

Read more »

Landlady greets regular at real ale pub
Investing Articles

£5,000 invested in Diageo shares 110 days ago is now worth…

With a new turnaround CEO at the helm, Diageo shares could be about to enjoy a recovery rally. But how…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

How Lloyds shares could rise to 131p… or sink to 91p

Lloyds shares are extremely volatile against the backdrop of the Middle East crisis. The question is, where might the FTSE…

Read more »

A hiker and their dog walking towards the mountain summit of High Spy from Maiden Moor at sunrise
Investing Articles

I’m ignoring gold and hunting FTSE 100 shares to buy as I aim for an earlier retirement

With some FTSE large-caps falling, bargain shares to buy have started emerging that might deliver far better returns than gold…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Growth stocks or dividend shares? You don’t have to choose!

Not all dividend stocks are the same. Here’s what Warren Buffett says separates the good from the truly exceptional for…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Here’s how to invest £5,000 in an ISA for a 7.41% dividend yield

There are almost 30 companies in the FTSE 350 paying a 7%+ dividend yield in April, but which ones are…

Read more »